ClinicalTrials.gg
Not yet recruitingNCT07690319EARLY-HS 2Updated Oct 20, 2026

A Study of Early Secukinumab Treatment in Moderate to Severe Hidradenitis Suppurativa Patients

An observational study in Hidradenitis Suppurativa, sponsored by Novartis Pharmaceuticals. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Observational

How we know

Updated Oct 20, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
186
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies in Hidradenitis Suppurativa by Novartis — 9 open to participants now, 14 under way, 3 of them phase 3. Hidradenitis Suppurativa · Novartis.

Planned enrollment
4th of 10
186 · median 125
Started
2026
with 4 others
Observational
10 of 21
6 open now
Primary completion
2027-03
later than 2 of 13 live
Registered
20th of 21
by date

Among the 21 studies in Hidradenitis Suppurativa by Novartis, this one is the 4th largest by planned enrollment of the 10 observational ones that give a count, is one of 5 that started in 2026, is one of 10 observational ones, reaches primary completion later than 2 of the 13 other live ones, and was the 20th registered.

Hidradenitis Suppurativa

286 studies on the registry are indexed under Hidradenitis Suppurativa; 89 are open to participants now.

Browse Hidradenitis Suppurativa studies →

Open to participants now

9 of the 21 studies in Hidradenitis Suppurativa by Novartis are open now, in 12 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Who these studies take

Of the 63 Hidradenitis Suppurativa studies recruiting now, 35 (56%) set no upper age limit and 17 (27%) stop at 75 or younger; 13 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Hidradenitis Suppurativa by Novartis, or all of them as a file.
02

Study summary

The aim of this study is to evaluate the effectiveness of early treatment with secukinumab in patients with moderate-to-severe hidradenitis suppurativa (HS) and assess its impact on disease progression using data from multiple European data sources. All data will be sourced from existing non-interventional study primary data collection, registries, and hospital cohorts that captured information collected in routine clinical practice, prior to and independent of this study.

03

Conditions studied

  • Hidradenitis Suppurativa

Keywords

  • Hidradenitis Suppurativa
  • Secukinumab
  • Early treatment
  • Real-world evidence
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult patients with moderate-to-severe HS who initiated secukinumab treatment.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with a documented diagnosis of HS (e.g., International Classification of Diseases, 10th Revision [ICD-10] code L73.2);
  • Age ≥18 years at index date;
  • Moderate-to-severe HS as per label;
  • Initiation of secukinumab treatment on or after the first HS diagnosis date;
  • And at least one follow-up assessment at 6 or 12 months after index date.

Exclusion criteria

Exclusion criteria:

  • Patients who had major HS-related surgery (Skin-tissue-sparing Excision with Electrosurgical Peeling [STEEP] or wide excision) in the 12 months prior to index date;
  • Patients participating in interventional clinical trials at index date.

Other protocol-defined inclusion/exclusion criteria may apply.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
186 participants (estimated)
Patient registry
No

Groups and cohorts

  • Early Treatment Group

    Adult patients with moderate to severe HS, having up to 1 active tunnel (draining or non-draining) or up to 4 inflammatory lesions (abscess/nodules) at date of first secukinumab administration for HS treatment.

  • Late Treatment Group

    Adult patients with moderate to severe HS, having \>1 active tunnel or \>4 inflammatory lesions, at date of first secukinumab administration for HS treatment.

06

What researchers measure

Primary outcomes

  1. Proportion of Patients Achieving 55% Reduction From Baseline in International Hidradenitis Suppurativa Severity Scoring System (IHS4-55) at 6 and 12 Months

    The International Hidradenitis Suppurativa Severity Scoring System (IHS4) is a validated measure of HS severity. Disease severity is calculated by weighting different lesion types as follows: the IHS4 score = (number of nodules × 1) + (number of abscesses × 2) + (number of draining tunnels \[fistulae/sinuses\] × 4). A score of ≤3 indicates mild disease, a score of 4-10 indicates moderate disease, and a score of ≥11 indicates severe disease. In this study, treatment response is assessed using IHS4-55, defined as a proportion of patients achieving ≥55% reduction in IHS4 score compared to baseline.

    Time frame: 6 and 12 months

Secondary outcomes

  1. Number and Percentage of Patients by Selected Demographic and Clinical Characteristics Overall and by Early and Late Treatment Group

    Demographics and clinical characteristics (subject to availability in the data sources) include: * Age category * Sex * Body mass index (BMI) category * Smoking status * Other medical conditions * Family history of HS * Year of HS diagnosis * Year of secukinumab initiation * Hurley stage * Number of tunnels, nodules, abscesses * Prior surgeries and procedures * Prior treatment

    Time frame: Baseline

  2. Duration of HS

    Time frame: Baseline

  3. Mean Change From Baseline in IHS4 Score at 6 and 12 Months

    The IHS4 is a validated measure of HS severity. Disease severity is calculated by weighting different lesion types as follows: the IHS4 score = (number of nodules × 1) + (number of abscesses × 2) + (number of draining tunnels \[fistulae/sinuses\] × 4). A score of ≤3 indicates mild disease, a score of 4-10 indicates moderate disease, and a score of ≥11 indicates severe disease.

    Time frame: Baseline, 6 and 12 months

  4. Proportion of Patients Achieving 75% Reduction in IHS4 (IHS4-75) From Baseline at 6 and 12 Months

    The IHS4 is a validated measure of HS severity. Disease severity is calculated by weighting different lesion types as follows: the IHS4 score = (number of nodules × 1) + (number of abscesses × 2) + (number of draining tunnels \[fistulae/sinuses\] × 4). A score of ≤3 indicates mild disease, a score of 4-10 indicates moderate disease, and a score of ≥11 indicates severe disease. IHS4-75 is defined as a proportion of patients achieving ≥ 75% reduction in IHS4 score at 6 and 12 months compared to baseline.

    Time frame: 6 and 12 months

  5. Proportion of Patients Achieving 100% Reduction in IHS4 (IHS4-100) From Baseline at 6 and 12 Months

    The IHS4 is a validated measure of HS severity. Disease severity is calculated by weighting different lesion types as follows: the IHS4 score = (number of nodules × 1) + (number of abscesses × 2) + (number of draining tunnels \[fistulae/sinuses\] × 4). A score of ≤3 indicates mild disease, a score of 4-10 indicates moderate disease, and a score of ≥11 indicates severe disease. IHS4-100 is defined as a proportion of patients achieving 100% reduction in IHS4 score at 6 and 12 months compared to baseline.

    Time frame: 6 and 12 months

  6. Mean Change in Number of Inflammatory Abscesses, Nodules, and Active Tunnels From Baseline at 6 and 12 Months

    Time frame: Baseline, 6 and 12 months

  7. Proportion of Patients Whose Disease Progresses From Baseline at 6 and 12 Months

    Disease progression is defined as development of new tunnel(s) or development of new persistent HS lesions in an anatomical area not previously affected or increase in the number of persistent HS lesions in an affected anatomical region. Persistent lesions are defined as lesions sustained for ≥4 weeks.

    Time frame: 6 and 12 months

  8. Mean Number of Flares From Baseline at 6 and 12 Months

    Flare is defined as an increase of at least 25% in AN (abscess and inflammatory nodule) count with a minimum increase of 2 AN relative to baseline.

    Time frame: 6 and 12 months

  9. Mean Change in Pain From Baseline at 6 and 12 Months

    Patient-reported Numeric Rating Scale (NRS) skin pain score at 6 and/or 12 months, as recorded. The Skin Pain NRS is a tool used to measure patient reported skin pain severity. Patients rate their worst skin pain over the past 24 hours on a scale from 0 (no pain) to 10 (worst pain imaginable).

    Time frame: Baseline, 6 and 12 months

  10. Proportion of Patients Achieving ≥30% Reduction in Patient's Global Assessment of Skin Pain Numeric Rating Scale (NRS30)

    The Skin Pain NRS is a tool used to measure patient reported skin pain severity. Patients rate their worst skin pain over the past 24 hours on a scale from 0 (no pain) to 10 (worst pain imaginable). An NRS30 response is defined as a ≥30% reduction and ≥2-point decrease in skin pain score from baseline.

    Time frame: 6 and 12 months

  11. Proportion of Patients Who Required Surgery From Baseline at 6 and 12 Months

    Any HS-related surgery (e.g., STEEP, wide excision, incision and drainage, deroofing) between baseline and at 6 and/or 12 months, as reported.

    Time frame: 6 and 12 months

  12. Proportion of Patients Achieving a 5-point Reduction of Their Dermatology Life Quality Index (DLQI) Questionnaire From Baseline at 6 and 12 Months

    The DLQI is a questionnaire designed to measure the impact of skin disease on a patient's health-related quality of life. It contains 10 simple, self-administered items. Each item is scored on a 4-point scale (0 = not at all to 3 = very much). The total score ranges from 0 to 30, with higher scores indicating greater impairment in quality of life.

    Time frame: 6 and 12 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Nov 2026; primary completion for Mar 2027, 4 months later.

Start moved once since we started tracking on Sep 25, 2026: Oct 2026 → Nov 2026, on Oct 20, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 2, 2026
First posted
Jul 8, 2026
StartEst.
Nov 13, 2026was Oct 2026
Primary completionEst.
Mar 15, 2027
CompletionEst.
Mar 15, 2027
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Oct 15, 2026→Nov 13, 2026
Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    Start date Oct 15, 2026→Nov 13, 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07690319
Responsible party
Sponsor
First posted
Jul 8, 2026
Start date
Nov 13, 2026 (estimated)
Primary completion
Mar 15, 2027 (estimated)
Completion
Mar 15, 2027 (estimated)
Last update
Oct 20, 2026

Study contacts

Novartis Pharmaceuticals
Contact
novartis.email@novartis.com
+41613241111
Novartis Pharmaceuticals
Contact
Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion